Cargando…
A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome
BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system fo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951779/ https://www.ncbi.nlm.nih.gov/pubmed/36846732 http://dx.doi.org/10.4103/1735-5362.363599 |
_version_ | 1784893465215107072 |
---|---|
author | Heydari, Parisa Ghanadian, Mustafa Asghari, Gholamreza Azimi, Maryam Babaeian, Mahmoud Adibi, Peyman |
author_facet | Heydari, Parisa Ghanadian, Mustafa Asghari, Gholamreza Azimi, Maryam Babaeian, Mahmoud Adibi, Peyman |
author_sort | Heydari, Parisa |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system for IBS, people in the western world use different herbs as alternative medicine. In the present study, we evaluated the dried extract of Dracocephalum kotschyi against IBS. EXPERIMENTAL APPROACH: In a randomized, double-blinded, placebo-controlled clinical trial, 76 diarrhea-predominant IBS patients were randomly assigned to two equal groups: the control group (given the placebo capsule containing 250 mg of dibasic calcium phosphate) and the treatment groups (given the capsule containing 75 mg of the dry extract of D. kotschyi and 175 mg of dibasic calcium phosphate as filler). The study was conducted based on Rome III criteria. We studied symptoms included in Rome III criteria and divided the study into the duration of drug administration and four weeks after drug administration. These groups were compared with those of the control group. FINDINGS/RESULTS: Significant improvements were found in the quality of life, temperament, and IBS symptoms throughout the treatment duration. Quality of life, temperature, and IBS symptoms were slightly decreased in the treatment group 4 weeks after stopping the treatment. While concluding the study, we found D. kotschyi effective against IBS. CONCLUSION AND IMPLICATIONS: Whole extract of D. kotschyi modulated symptoms of IBS patients and improved their quality of life. |
format | Online Article Text |
id | pubmed-9951779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-99517792023-02-25 A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome Heydari, Parisa Ghanadian, Mustafa Asghari, Gholamreza Azimi, Maryam Babaeian, Mahmoud Adibi, Peyman Res Pharm Sci Original Article BACKGROUND AND PURPOSE: Irritable bowel syndrome (IBS) is a disease that shows its impacts on many populations worldwide. It is known as a functional disorder of the gastrointestinal tract followed by diarrhea and fecal inconsistency. Due to the lack of treatment in the allopathic medicine system for IBS, people in the western world use different herbs as alternative medicine. In the present study, we evaluated the dried extract of Dracocephalum kotschyi against IBS. EXPERIMENTAL APPROACH: In a randomized, double-blinded, placebo-controlled clinical trial, 76 diarrhea-predominant IBS patients were randomly assigned to two equal groups: the control group (given the placebo capsule containing 250 mg of dibasic calcium phosphate) and the treatment groups (given the capsule containing 75 mg of the dry extract of D. kotschyi and 175 mg of dibasic calcium phosphate as filler). The study was conducted based on Rome III criteria. We studied symptoms included in Rome III criteria and divided the study into the duration of drug administration and four weeks after drug administration. These groups were compared with those of the control group. FINDINGS/RESULTS: Significant improvements were found in the quality of life, temperament, and IBS symptoms throughout the treatment duration. Quality of life, temperature, and IBS symptoms were slightly decreased in the treatment group 4 weeks after stopping the treatment. While concluding the study, we found D. kotschyi effective against IBS. CONCLUSION AND IMPLICATIONS: Whole extract of D. kotschyi modulated symptoms of IBS patients and improved their quality of life. Wolters Kluwer - Medknow 2022-12-24 /pmc/articles/PMC9951779/ /pubmed/36846732 http://dx.doi.org/10.4103/1735-5362.363599 Text en Copyright: © 2022 Research in Pharmaceutical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Heydari, Parisa Ghanadian, Mustafa Asghari, Gholamreza Azimi, Maryam Babaeian, Mahmoud Adibi, Peyman A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title | A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title_full | A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title_fullStr | A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title_full_unstemmed | A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title_short | A double-blind randomized clinical trial of Dracocephalum kotschyi Boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
title_sort | double-blind randomized clinical trial of dracocephalum kotschyi boiss. in the patients with diarrhea-predominant irritable bowel syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951779/ https://www.ncbi.nlm.nih.gov/pubmed/36846732 http://dx.doi.org/10.4103/1735-5362.363599 |
work_keys_str_mv | AT heydariparisa adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT ghanadianmustafa adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT asgharigholamreza adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT azimimaryam adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT babaeianmahmoud adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT adibipeyman adoubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT heydariparisa doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT ghanadianmustafa doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT asgharigholamreza doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT azimimaryam doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT babaeianmahmoud doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome AT adibipeyman doubleblindrandomizedclinicaltrialofdracocephalumkotschyiboissinthepatientswithdiarrheapredominantirritablebowelsyndrome |